Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies

The Journal of General Virology
Véronique MerssemanSabine Reyda

Abstract

Exogenous introduction of particle-associated proteins of human cytomegalovirus (HCMV) into the major histocompatibility complex (MHC) class I presentation pathway by subviral dense bodies (DB) is an effective way to sensitize cells against CD8 T-cell (CTL) recognition and killing. Consequently, these particles have been proposed as a platform for vaccine development. We have developed a strategy to refine the antigenic composition of DB. For proof of principle, an HCMV recombinant (RV-VM3) was generated that encoded the immunodominant CTL determinant IE1TMY from the IE1 protein in fusion with the major constituent of DB, the tegument protein pp65. To generate RV-VM3, a bacterial artificial chromosome containing the HCMV genome was modified by applying positive/negative selection based on the expression of the bacterial galactokinase in conjunction with lambda Red-mediated homologous recombination. This method allowed the efficient and seamless insertion of the DNA sequence encoding IE1TMY in frame into the pp65 open reading frame (UL83) of the viral genome. RV-VM3 expressed its fusion protein to high levels. The fusion protein was packaged into DB and into virions. Its delivery into fibroblasts by these viral particles led to ...Continue Reading

References

Oct 1, 1972·Journal of Virology·J E CraigheadJ D Almeida
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·M MesserleU H Koszinowski
Sep 10, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Christine S FalkGabriele Hahn
Oct 4, 2002·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Sandra Pepperl-KlindworthBodo Plachter
Nov 5, 2002·Nature Reviews. Immunology·Matthias J Reddehase
Feb 7, 2003·Gene Therapy·S Pepperl-KlindworthB Plachter
Sep 29, 2004·Journal of Virology·Susan M VarnumJay A Nelson
Feb 26, 2005·Nucleic Acids Research·Søren WarmingNeal G Copeland
Mar 30, 2005·The Journal of Experimental Medicine·Torsten BundeFlorian Kern
Jul 20, 2005·Expert Review of Vaccines·Mark R Schleiss, Thomas C Heineman
Sep 9, 2005·The Journal of Experimental Medicine·Andrew W SylwesterLouis J Picker
Aug 25, 2006·Journal of Virology·Christian O SimonNatascha K A Grzimek
Feb 6, 2007·Parasitology·W I Morrison, D J McKeever
Jun 6, 2007·Expert Review of Anti-infective Therapy·Jie Zhong, Rajiv Khanna
Apr 25, 2008·Current Protocols in Immunology·Eva Maria BorstMartin Messerle

❮ Previous
Next ❯

Citations

Feb 28, 2008·Medical Microbiology and Immunology·Katrin Besold, Bodo Plachter
Mar 6, 2008·Medical Microbiology and Immunology·Véronique MerssemanSabine Reyda
Feb 21, 2009·The EMBO Journal·Martin GamerdingerChristian Behl
Dec 3, 2004·Drug Discovery Today·Jamal Temsamani, Pierre Vidal
Jul 25, 2009·Expert Review of Vaccines·Wolfgang Herr, Bodo Plachter

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Artificial Chromosomes

Artificial chromosomes are genetically engineered chromosomes derived from the DNA of a species. Discover the latest research on artificial chromosomes here.